Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Jun 4

PMID 31156651

Citations 38

Authors

Zenan Wang

Zhan Wang

Binghao Li

Shengdong Wang

Tao Chen

Zhaoming Ye

Affiliations

Soon will be listed here.

Abstract

Advanced, recurrent, or metastasized osteosarcomas remain challenging to cure or even alleviate. Therefore, the development of novel therapeutic strategies is urgently needed. Cancer immunotherapy has greatly improved in recent years, with options including adoptive cellular therapy, vaccination, and checkpoint inhibitors. As such, immunotherapy is becoming a potential strategy for the treatment of osteosarcoma. Innate immunocytes, the first line of defense in the immune system and the bridge to adaptive immunity, are one of the vital effector cell subpopulations in cancer immunotherapy. Innate immune cell-based therapy has shown potent antitumor activity against hematologic malignancies and some solid tumors, including osteosarcoma. Importantly, some immune checkpoints are expressed on both innate and adaptive immune cells, modulating their functions in tumor immunity. Therefore, blocking or activating immune checkpoint-mediated downstream signaling pathways can improve the therapeutic effects of innate immune cell-based therapy. In this review, we summarize the current status and future prospects of innate immune cell-based therapy for the treatment of osteosarcoma, with a focus on the potential synergistic effects of combination therapy involving innate immunotherapy and immune checkpoint inhibitors/oncolytic viruses.

Citing Articles

Identification of the shared gene signatures in retinoblastoma and osteosarcoma by machine learning.

Ye R, Yuan Q, You W, Huang Y, Lin Z, Tang H Sci Rep. 2024; 14(1):31355.

PMID: 39733097 PMC: 11682156. DOI: 10.1038/s41598-024-82789-7.

PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs.

Dziubek K, Faktor J, Lokhande K, Shrivastava A, Papak I, Chrusciel E Cell Commun Signal. 2024; 22(1):605.

PMID: 39696578 PMC: 11658327. DOI: 10.1186/s12964-024-01935-w.

Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma.

Lacinski R, Dziadowicz S, Melemai V, Fitzpatrick B, Pisquiy J, Heim T Bone Res. 2024; 12(1):55.

PMID: 39333065 PMC: 11436896. DOI: 10.1038/s41413-024-00359-z.

Development and experimental validation of hypoxia-related gene signatures for osteosarcoma diagnosis and prognosis based on WGCNA and machine learning.

Wen B, Chen J, Ding T, Mao Z, Jin R, Wang Y Sci Rep. 2024; 14(1):18734.

PMID: 39134603 PMC: 11319349. DOI: 10.1038/s41598-024-69638-3.

Teng J, Wang Y Sci Rep. 2024; 14(1):13401.

PMID: 38862526 PMC: 11166963. DOI: 10.1038/s41598-024-54292-6.

References

Meneghetti A, Mariani E, Santi S, Riccio M, Cattini L, Paoletti S . NK binding capacity and lytic activity depend on the expression of ICAM-1 on target bone tumours. Int J Oncol. 1999; 15(5):909-14. DOI: 10.3892/ijo.15.5.909. View

Mariani E, Meneghetti A, Tarozzi A, Cattini L, Facchini A . Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand J Immunol. 2000; 51(6):618-25. DOI: 10.1046/j.1365-3083.2000.00737.x. View

den Haan J, Lehar S, Bevan M . CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000; 192(12):1685-96. PMC: 2213493. DOI: 10.1084/jem.192.12.1685. View

Tahir S, Cheng O, Shaulov A, Koezuka Y, Bubley G, Wilson S . Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 2001; 167(7):4046-50. DOI: 10.4049/jimmunol.167.7.4046. View

Girardi M, Oppenheim D, Steele C, Lewis J, Glusac E, Filler R . Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001; 294(5542):605-9. DOI: 10.1126/science.1063916. View

Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N . Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol. 2001; 167(9):5092-8. DOI: 10.4049/jimmunol.167.9.5092. View

Synnestvedt K, Furuta G, Comerford K, Louis N, Karhausen J, Eltzschig H . Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002; 110(7):993-1002. PMC: 151145. DOI: 10.1172/JCI15337. View

Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S . Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002; 42(11):1228-36. DOI: 10.1177/009127002762491316. View

Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A . Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood. 2002; 101(10):3985-90. DOI: 10.1182/blood-2002-07-2113. View

10.

Metelitsa L, Weinberg K, Emanuel P, Seeger R . Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003; 17(6):1068-77. DOI: 10.1038/sj.leu.2402943. View

11.

Kenna T, Golden-Mason L, Porcelli S, Koezuka Y, Hegarty J, OFarrelly C . NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol. 2003; 171(4):1775-9. DOI: 10.4049/jimmunol.171.4.1775. View

12.

Luksch R, Perotti D, Cefalo G, Passerini C, Massimino M, Spreafico F . Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori. 2003; 89(3):263-8. DOI: 10.1177/030089160308900306. View

13.

Rosen L, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M . Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21(16):3150-7. DOI: 10.1200/JCO.2003.04.105. View

14.

Honorati M, Neri S, Cattini L, Facchini A . IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 2003; 133(3):344-9. PMC: 1808781. DOI: 10.1046/j.1365-2249.2003.02234.x. View

15.

Crowe N, Uldrich A, Kyparissoudis K, Hammond K, Hayakawa Y, Sidobre S . Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol. 2003; 171(8):4020-7. DOI: 10.4049/jimmunol.171.8.4020. View

16.

Liebau C, Merk H, Schmidt S, Roesel C, Karreman C, Prisack J . Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol Ther. 2003; 7(4):135-42. DOI: 10.1080/13684730310001977. View

17.

Lozupone F, Pende D, Burgio V, Castelli C, Spada M, Venditti M . Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res. 2004; 64(1):378-85. DOI: 10.1158/0008-5472.can-03-1501. View

18.

Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun G, Fautsch S . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105(8):3051-7. DOI: 10.1182/blood-2004-07-2974. View

19.

Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M . A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005; 11(5):1910-7. DOI: 10.1158/1078-0432.CCR-04-1453. View

20.

Wongkajornsilp A, Sangsuriyong S, Hongeng S, Waikakul S, Asavamongkolkul A, Huabprasert S . Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J Orthop Res. 2005; 23(6):1460-6. DOI: 10.1016/j.orthres.2005.03.009.1100230632. View